MaxCyte, Inc.
22 Firstfield Road, Suite 110
Gaithersburg
Maryland
20878
United States
Tel: 1-301-944-1700
Fax: 1-301-944-1703
Website: http://www.maxcyte.com/
Email: careers@maxcyte.com
About MaxCyte, Inc.
We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.
This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell-engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines.
We are also developing novel CARMA cellular therapies for our own pipeline with our first drug candidate in a Phase I clinical trial. CARMA is MaxCyte’s novel proprietary technology for development of human mRNA-based cellular therapies to treat a broad range of diseases.
Stock Exchange: Alternative Investment Market
Stock Symbol: MXCT
At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use, more cost-effectively and with lowered risk. We have developed and commercialized MaxCyte Scalable Transfection Systems for high-performance delivery of biomolecules using Flow Electroporation ® Technology, a proprietary cell-engineering technology designed to meet the stringent demands of clinical use – namely, the ability to safely and reproducibly modify primary human cells with high efficiency, low cytotoxicity, and at the scale required to treat patients.
142 articles with MaxCyte, Inc.
-
MaxCyte, Inc. Introduces Rapid, Automated, Scalable Flow Electroporation-Based Technology For Vaccine Development
3/20/2014
-
MaxCyte, Inc. Introduces The 2014 Maxcyte STX Scalable Transfection System For Cell-Based Assay Applications At The SLAS 2014 Annual Conference & Exhibition
1/20/2014
-
MaxCyte, Inc. Presents Data On Stable Cell Line Generation And Rapid, High Titer Production Of Antibodies And Proteins Using Flow Electroporation
12/9/2013
-
MaxCyte, Inc. Presents Data On Stable Cell Line Generation And Rapid, High Titer Production Of Antibodies And Proteins Using Flow Electroporation
12/9/2013
-
MaxCyte, Inc. Presents Scalable Flow Electroporation as a Universal Platform for High Titer Antibody and Protein Production at CHI’s PEGS Europe Summit
11/4/2013
-
MaxCyte, Inc. Presents Large Scale Flow Electroporation for Process Development and Bioproduction at CHI’s 2013 BioProcessing Summit
8/19/2013
-
Gram Scale Transient Antibody Production in CHO Cells With MaxCyte, Inc. Electroporation
6/18/2013
-
MaxCyte, Inc. Presents Unprecedented Data Using Flow Electroporation for CHO-Based Transient Gene Expression to Achieve Gram Scale Antibody Production and Rapid Stable Cell Line Generation
5/20/2013
-
MaxCyte, Inc. Presents Unprecedented Data Using Flow Electroporation for CHO-Based Transient Gene Expression to Achieve Gram Scale Antibody Production and Rapid Stable Cell Line Generation
5/20/2013
-
MaxCyte, Inc. CEO Doug Doerfler Named Chairman of the Tech Council of Maryland
5/17/2013
-
MaxCyte, Inc. Presents Unprecedented CHO-Based Transient Gene Expression Data for Gram Scale Antibody Production and Rapid Stable Cell Line Generation at CHI’s 2013 Protein and Antibody Engineering Summit (PEGS)
4/26/2013
-
MaxCyte, Inc.® VLX and STX Transient Transfection Systems Are Acquired by Paragon Bioservices for Use in Vaccine and Protein Manufacturing
1/29/2013
-
MaxCyte, Inc. Highlights Innovations in Scalable, High-Throughput Transient Transfection for Streamlining Antibody Development and Production at PepTalk 2013, Booth #307
1/22/2013
-
MaxCyte, Inc. Highlights Innovations in Scalable, High-Throughput Transfection for Cell-Based Assays at the SLAS2013 Conference and Exhibition in Orlando, Booth #428
1/11/2013
-
MaxCyte, Inc. Announces a Business & Technical Update at Biotech Showcase 2013
1/4/2013
-
MaxCyte, Inc. Highlights High Titer Protein Production Using Biologically Relevant Cells in an Upcoming Educational Webinar Presentation
12/11/2012
-
MaxCyte, Inc. Highlights Gram Scale Protein Production Capability Using CHO Transient Transfection in an Upcoming Educational Webinar Presentation
3/21/2012
-
MaxCyte, Inc. Highlights Gram-Scale Antibody & Protein Production from Transient Transfection of CHO Cells and MaxCyte® VLX™ Large Scale Transfection System Launch
2/13/2012
-
MaxCyte, Inc. Highlights Innovations in Scalable, High-Throughput Transfection for Cell-Based Assays & Protein Production at the SLAS2012 Conference and Exhibition in San Diego, Booth #848
2/6/2012
-
MaxCyte, Inc. Announces Gram-Scale Antibody & Protein Production from the Transient Transfection of CHO Cells
1/30/2012